(Bloomberg) -- As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.

Claim your 7-day free trial now. Novo Nordisk A/S NVO on Saturday presented the full results from the Phase 3b STRIDE peripheral artery disease (PAD) outcomes trial. The study evaluated the once ...

Danish drugmaker Novo Nordisk has been dethroned by German software giant SAP as Europe’s most valuable company. SAP has soared some 40 per cent over the last year as investors celebrated its ...

Well before market open that morning, Morgan Stanley's Thibault Boutherin knocked his Novo Nordisk price target down to 600 Danish kroner ($86.67) per share; previously, this number was 700 kroner ...

Sex scenes are everywhere in TV and film, but sometimes they are more real than you'd like to think Sex in TV and film is something that we're all used to seeing by now, but unsimulated intercourse is ...

Novo Nordisk falder nok engang torsdag på aktiemarkedet. Amerikanske storbank tror nu samtidig mindre på den danske folkeaktie og sænker derfor sit kursmål Novo Nordisk fortsætter til stor ...

A U.S. federal court has approved a settlement between Novo Nordisk (NVO) and Minnesota ending a longstanding litigation that accused three leading insulin manufacturers of charging excessive ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) built its business on insulin and has emerged as a leading innovator in GLP-1 agonists, relatively new drugs that treat obesity and type 2 diabetes by ...

There is a long-running health crisis impacting the modern world. According to the World Health Organization, one in eight people worldwide were living with obesity as of 2022. Obesity causes ...

The popularity of Novo Nordisk's Ozempic and Wegovy has attracted competitors and created supply constraints. Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III ...

The Chinese blockbuster, which continues the mythological story of its 2019 predecessor, became one of the highest openings for a Chinese film in the territory. It has earned more than $2 billion ...

Less than five years on from when Novo Nordisk's semaglutide drug received FDA approval for weight loss (Wegovy), the Danish pharmaceutical company has announced it will seek regulatory approval ...